Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TK1 | P04183 | 2/20 | 0.51 |
| ▸ | TYMP | P19971 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403292 | 0.84 | MAPK1 (0.54) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL2183944 | 0.79 | MAPK1 (0.61) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL27708058 | 0.77 | MAPK1 (0.59) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL1058809 | 0.77 | MAPK1 (0.59) | MAPK1HPGDTK1TYMPALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4194711 | 0.77 | MAPK1 (0.59) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL15110503 | 0.77 | TK2 (0.60) | MAPK1HPGDTK1TYMPTK2 | |
| SCHEMBL26034737 | 0.77 | MAPK1 (0.59) | MAPK1HPGDTK1TYMP | |
| SCHEMBL23873105 | 0.76 | TYMP (0.58) | MAPK1HPGDTK1TYMP | |
| SCHEMBL16380799 | 0.76 | TYMP (0.58) | MAPK1HPGDTK1TYMP | |
| SCHEMBL7215300 | 0.76 | MAPK1 (0.57) | MAPK1HPGDTK1TYMPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037082-A1 | SYNTHETIC PEPTIDES, ENZYMATIC FORMATION OF PERICELLULAR HYDROGELS/NANOFIBRILS, AND METHODS OF USE | BRANDEIS UNIVERSITY | 2017-02-09 | — | — | US | claimed |
| WO-2015157535-A2 | SYNTHETIC PEPTIDES, ENZYMATIC FORMATION OF PERICELLULAR HYDROGELS/NANOFIBRILS, AND METHODS OF USE | BRANDEIS UNIVERSITY (US) | 2015-10-15 | — | — | WO | claimed |
| US-6359061-B1 | COMBINATORIAL LIBRARIES ARE USEFUL FOR SCREENING IN BIOLOGCAL ASSAYS IN ORDER TO IDENTIFY PHARMACEUTICALLY USEFUL COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| US-6316623-B1 | USEFUL FOR SCREENING IN BIOLOGICAL ASSAYS IN ORDER TO IDENTIFY PHARMACEUTICALLY USEFUL COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | claimed |
| US-11839661-B2 | Rapid formation of supramolecular hydrogels by short peptide and bioactive small molecules | BRANDEIS UNIVERSITY (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210128745-A1 | RAPID FORMATION OF SUPRAMOLECULAR HYDROGELS BY SHORT PEPTIDE AND BIOACTIVE SMALL MOLECULES | BRANDEIS UNIVERSITY | 2021-05-06 | — | — | US | disclosed |
| WO-2019035928-A1 | RAPID FORMATION OF SUPRAMOLECULAR HYDROGELS BY SHORT PEPTIDE AND BIOACTIVE SMALL MOLECULES | BRANDEIS UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
| US-8188011-B1 | Optimization of ligand affinity for RNA targets using mass spectrometry | ISIS PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20050142581-A1 | Microrna as ligands and target molecules | ISIS PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| US-6849660-B1 | Antimicrobial biaryl compounds | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-6828427-B1 | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same | ISIS PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| US-6770486-B1 | IDENTIFICATION OF LIGAND COMPOUNDS THAT BIND TO TARGET MOLECULES SUCH AS PROTEINS OR STRUCTURED RNA WITH AS LITTLE AS MILLIMOLAR (MM) AFFINITY USING MASS SPECTROMETRY | ISIS PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| US-6204326-B1 | ADDING PEPTIDE NUCLEIC ACID UNITS TO AN AMINE TERMINATED PEPTIDE NUCLEIC ACID OLIGOMER ON A SOLID PHASE SYNTHETIC RESIN; BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-0777678-B1 | PNA COMBINATORIAL LIBRARIES AND IMPROVED METHODS OF SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5864010-A | ENZYME INHIBITOR; ANTIINFLAMMATORY AGENT | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0865439-A4 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS INC (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5831014-A | OLIGOMERS WITH PEPTIDE NUCLEIC ACID UNITS AND AMINO ACID UNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0865439-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-23 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5539083-A | FROM HALOACETYL HALIDE OR SULFONYLACETYL HALIDE, PROTECTED ALKYLENEDIAMINE, AND A DERIVATIVE OF A NUCLEIC ACID BASE | ISIS PHARMACEUTICALS, INC. (US) | 1996-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037082-A1 | SYNTHETIC PEPTIDES, ENZYMATIC FORMATION OF PERICELLULAR HYDROGELS/NANOFIBRILS, AND METHODS OF USE | DNPEP, ENPEP, ANPEP | MAPK1 1658/4885HPGD 3290/4885TK1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.